[ Inside the business ]

RMD stock analysis

RMD · Resmed Inc

Surgical and medical instruments and apparatus. Growing 6%. Keeps 33¢ of every dollar.

Watch: a leadership change, growth that has stopped speeding up.

The future, in 7 questions

Priced in: 2.3× sales in 5 yrs. Evidence: sales +6% · 33¢ profit/$1.

01 What's priced in?2.3× sales in 5 yrs
Sales now$5.7B
Needed in 5 yrs$13.4B
Backlog$386M
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +6%, steady
No customer over 10%
Backlog $386M · under 0.1× salesPrepaid $172MSales +6%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 33¢ per $1, rising
'22'23'24'25'2633¢
Before running costs: 56% → 61%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −0.5%/yrDebt $410M
07 What could break it?2 to watch
  • Growth slowing
  • Moves strongly with the 10Y yield

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +11%, +9%, then +6% vs. a year ago. A leadership change was filed on Nov 19.

What could go wrong

Steadier than most.

It has moved 0.5× the market. In the 2022 rate shock it fell 16% while the market fell 24%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

88% Sleep and Breathing Health.

Sleep and Breathing Health 88% · Residential Care Software 12%

Where each dollar goes

33¢ profit.

39¢ to make what it sells, 28¢ on research and overhead, 33¢ left over. Revenue $5.7B in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 111¢ of each $1 of profit.

Competitive advantage

10 of 10 years.

Returns beat its 8.7% cost of capital in 10 of the last 10 years. Gross margin went from 58% to 61%.

Future bets

7% on research.

$392M a year on R&D. $162M on equipment and buildings.

All figures from Resmed Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.